You are here: Industry Insights > Bispecific Antibodies

News List

An Overview of the Research Advancements in Bispecific Antibodies Dopine/PharmaSources
August 30, 2023
According to the Pharmacodia Database, currently, there have been 13 drugs approved worldwide in this field. However, Removab was withdrawn from the market in 2017 due to its strong immunogenicity and commercial reasons.
Innovent Biologics enters drug development deal with Roche pharmaceutical-technology
June 10, 2020
Chinese biopharmaceutical firm Innovent Biologics has entered a strategic research and development partnership with Roche for various cell therapies and bispecific antibodies.
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases En-CPhI.CN
January 09, 2020
WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
GSK expands bispecific antibodies deal with Zymeworks pharmaceutical-technology
May 22, 2019
GlaxoSmithKline (GSK) has expanded its licensing and collaboration agreement with Canadian biotechnology firm Zymeworks.
Abpro, NJCTTQ to develop multiple novel bispecific antibodies biospectrumasia
March 04, 2019
NJCTTQ to have exclusive commercial rights to approved molecules in China; Abpro to retain commercial rights for all other major regions.
EpimAb announces IND filing for EMB01 biospectrumasia
September 18, 2018
IND filing marks further progress towards the first clinical trial with the Company’s Novel Bispecific Antibody Format.
F-Star Expands Relationship with Merck to Develop Bispecific Antibodies in Immuno-Oncology americanpharmaceuticalreview
June 07, 2017
F-star announced a new partnership with Merck for the development and commercialization of five bispecific immuno-oncology antibodies (mAb2).